Key Insights

Highlights

Treatment Research

1 treatments under study, led by Blinatumomab In Combination With Donor Lymphocyte Infusion

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Withdrawn1

Clinical Trials (1)

Showing 1 of 1 trials
NCT03982992Phase 2WithdrawnPrimary

Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab

Showing all 1 trials

Research Network

Common Treatments

  • Blinatumomab In Combination With Donor Lymphocyte Infusion1

Active Sponsors

  • Amgen1
  • Ludwig-Maximilians - University of Munich1

Top Investigators

Related Conditions

  • Acute Lymphoblastic Leukemia1
  • Acute Lymphoblastic Leukemia In Remission1
  • Acute Lymphoblastic Leukemia Adult1
  • Bcell Acute Lymphoblastic Leukemia1

Activity Timeline